Fendiline: Difference between revisions
CSV import |
CSV import |
||
| Line 27: | Line 27: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
<gallery> | |||
File:Fendiline.png|Fendiline | |||
</gallery> | |||
Revision as of 01:06, 20 February 2025
Fendiline is a calcium channel blocker that was originally developed for the treatment of angina pectoris. It is a non-selective calcium channel blocker and has been found to block L-type calcium channels. Fendiline has also been found to inhibit cell proliferation and induce apoptosis in various types of cancer cells.
Pharmacology
Fendiline is a non-selective calcium channel blocker that has been found to block L-type calcium channels. It has been found to inhibit cell proliferation and induce apoptosis in various types of cancer cells. The mechanism of action of fendiline in cancer cells is not fully understood, but it is thought to involve the inhibition of calcium influx into cells, which can lead to cell death.
Clinical uses
Fendiline was originally developed for the treatment of angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart. However, its use in this context has been largely superseded by newer and more effective medications.
More recently, fendiline has been investigated for its potential anti-cancer properties. Studies have found that fendiline can inhibit the growth of various types of cancer cells, including breast cancer, lung cancer, and leukemia cells. However, further research is needed to fully understand the potential of fendiline as a cancer treatment.
Side effects
Like other calcium channel blockers, fendiline can cause a range of side effects. These can include dizziness, flushing, headache, and swelling of the ankles or feet. In rare cases, fendiline can cause more serious side effects such as irregular heartbeat, severe dizziness, and fainting.
